Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts. by Hoyle, M & Anderson, R
Whose costs and benefits?  
 1 
Whose costs and benefits?  Why economic 
evaluations should simulate both prevalent and 
all future incident patient cohorts 
 
 
 
Martin Hoyle, PhD   Research Fellow 
Rob Anderson, PhD   Senior Lecturer 
 
Peninsula Technology Assessment Group (PenTAG), 
Peninsula Medical School,  
Universities of Exeter and Plymouth, Exeter. 
 
 
Correspondence and reprints to: 
Dr M Hoyle 
PenTAG 
Institute for Health Services Research 
Noy Scott House 
Royal Devon & Exeter Hospital 
Barrack Road 
Exeter   EX2 5DW 
United Kingdom 
 
Tel: +44 1392 406969 
Fax: +44 1392 406401 
email: martin.hoyle@pms.ac.uk 
 
Financial support:  The work reported in this paper was unfunded. 
Running head:  Whose costs and benefits? 
 
NB: An earlier version of this manuscript was discussed at the UK Health Economics 
Study Group winter meeting in January 2008. 
 
Word count: (excl Abstract, references, legends) = 5,749
Whose costs and benefits?  
 2 
Abstract 1 
Background  Most health technology economic evaluations simulate only the 2 
prevalent cohort, or the next incident cohort of patients.  They therefore do not 3 
capture all future patient-related benefits and costs. 4 
Objective  We show how to estimate and aggregate the ICERs for both currently 5 
eligible (prevalent) and future (incident) patient cohorts, within the same model-based 6 
analysis.  We show why, and in what circumstances, the prevalent and incident 7 
cohort ICERs are likely to differ. 8 
Methods  Algebraic expressions were developed to capture all components of the 9 
ICER in hypothetical cohorts of all prevalent patients and future incident patients.  10 
Numerical examples are used to illustrate the approach. 11 
Results  The ICER for the first (i.e. next) incident cohort is equivalent to the ICER for 12 
all future incident cohorts only when the discount rates for costs and benefits are the 13 
same; otherwise, when the discount rate for benefits is lower than for costs, the ICER 14 
for all future incident cohorts is lower than the ICER for the first incident cohort.  15 
Separate simulation of prevalent and incident patients treated for a hypothetical 16 
progressive chronic disease shows widely different ICERs according to which patient 17 
cohorts were included when the discount rates were equal. 18 
Conclusions  In many circumstances, both the prevalent cohort and all future 19 
incident cohorts should be modelled.  The need for this approach will depend on the 20 
likely difference in the ICERs for prevalent and incident patients, the relative size of 21 
the two types of cohort, and whether costs and benefits are discounted at equal 22 
rates. 23 
 24 
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Introduction 5 
It is increasingly recognised that to inform decision-making at a regional or national 6 
level, incremental cost-effectiveness ratios (ICERs) need to be based on rigorously 7 
informed decision model-based analyses which compare the incremental costs and 8 
effects of all relevant comparators, and typically for the remainder of patients’ 9 
lifetimes.1  Also, to be consistent with the fundamental tenets of cost-benefit analysis, 10 
such models should enable the valuation of costs and benefits “in each year of the 11 
project” (p.4), or for the whole of a health technology’s life.2   12 
The prevalence and incidence of a disease are fundamental concepts in 13 
epidemiology.  The prevalence is the number of cases in a population at a specified 14 
point in time, and the incidence is the number of new cases arising in a given period 15 
in a population.3  We apply the equivalent concepts of the prevalent cohort and future 16 
incident cohorts to model-based cost-effectiveness analysis.  We define the prevalent 17 
cohort as those patients eligible for the new technology at the time the technology is 18 
first introduced.  Any given patient will be eligible from the time when the technology 19 
is first clinically appropriate (e.g. just diagnosed with multiple sclerosis and eligible for 20 
drug treatment, or when first eligible for a hip replacement) until the time when the 21 
new technology is no longer appropriate (e.g. patient dies, or the disease has 22 
reached such a severe state that the drug is no longer effective, or the patient is too 23 
old to receive a hip replacement).  Next, we define the incident cohort starting t years 24 
in the future (i.e. t years after the date of a technology’s introduction) as comprising 25 
those patients who first become eligible for the new technology (e.g. diagnosed) t 26 
years in the future. 27 
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Cost-effectiveness studies generally model either only the first incident cohort 1 
of patients or only the prevalent cohort.  We argue first that model-based economic 2 
evaluations of new treatments should model the costs and benefits of all patients in 3 
the prevalent cohort and in all future incident cohorts over the life of the technology.  4 
We further recommend that overall cost-effectiveness should be based on all these 5 
cohorts combined, i.e. that the ICER be calculated from a weighted sum of all these 6 
costs and benefits. 7 
The current ISPOR guidance on good practice in decision analytic modelling 8 
focuses mainly on the structure of the model, the validation of the model 9 
estimates/inputs, and the choice between alternative simulation models (e.g. Monte 10 
Carlo vs. cohort).4  However, aside from some general encouragement to stratify 11 
models by patient sub-groups, there is no specific advice on what starting 12 
populations should go into a decision model.  Nor does methods guidance from 13 
national health technology assessment agencies state what current and future 14 
populations of patients should be included in model-based analyses, e.g. UK,5 15 
Australia,6 New Zealand,7 Canada,8 Germany.9 16 
In this paper, we describe the mathematics for estimating the ICER that 17 
includes the costs and benefits for both the prevalent and all future incident cohorts.  18 
For simplicity, we consider a new technology versus a single comparator technology, 19 
but the ‘comparator technology’ could represent no treatment.  Equivalent equations 20 
for more than two comparators in a net monetary benefit framework are given in the 21 
Online Appendix.  The technologies can be either a drug, a medical device, or a 22 
screening program.  We suggest parameters related to the structure of the patient 23 
cohorts that could be included in the probabilistic sensitivity analysis.   24 
 25 
 26 
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ICER for incident cohorts 1 
First future incident cohort 2 
Consider a cost-effectiveness model where future costs and benefits are modelled at 3 
discrete times (e.g. a Markov model).  Suppose the incremental costs, per patient 4 
starting treatment, between the new and comparator technology (where the 5 
comparator technology could be no technology, i.e. best supportive care), in cycles 0, 6 
1, 2,…., H are K0, K1, K2, …., KH and incremental benefits B0, B1, B2,…., 7 
BH (Table 1).  The time horizon is H cycles.  For clarity, given that the Kj and Bj 8 
are expressed per patient starting treatment, these quantities tend to zero with cycle 9 
j, as patients die.  Then the ICER as currently calculated for health technology 10 
assessments for the first future incident cohort, given discount rate for costs of r*C 11 
and benefits r*B over a cycle; 12 
 13 
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All future incident cohorts 18 
Now assume, more realistically, that a new cohort of patients will become eligible for 19 
treatment with the new or comparator technologies at the start of each of T years in 20 
the future.  The new and comparator technologies are assumed to become obsolete 21 
after T years, possibly replaced by another technology.  In this paper, we present all 22 
analyses with closed-form algebra to aid understanding of the methods.  However, it 23 
is of course possible to simulate each future incident cohort.  In general, assume that 24 
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 6 
the number of eligible patients at the start of each cohort, relative to the number of 1 
eligible patients at the start of the first year, is given by nt, at year t, so that n0 = 1.  2 
The nt are commonly used in budget impact analyses.  The nt could increase with 3 
year t, for example to model increasing numbers of Type 2 diabetes patients in the 4 
future as obesity becomes more common.  Assume further that the probability that an 5 
eligible patient is given the new technology in the tth year in the future is pt.  The pt 6 
could be described as the “rate of adoption”, “rate of uptake” or “market penetration” 7 
of the new technology, and are also commonly used in budget impact analyses.  The 8 
graph of the volume of sales of a drug, i.e. the product ntpt, against year t is 9 
generally -shaped.10  The annual volume of a drug sold typically increases in the 10 
first decade after drug launch, reflecting the diffusion of the new drug after launch.  11 
The annual volume of a drug sold in the second decade after launch reflects post-12 
patent experience and declines as patients switch to newer drugs.10;11  Then, the 13 
relative number of patients in the incident cohort starting t years in the future affected 14 
by the new technology is ntpt.  By analogy with the special case of two future incident 15 
cohorts (see Online Appendix); 16 
 17 
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, and Cr  and Br  are the “inter-generation” annual 20 
discount rates for costs and benefits between the current time and the time of the 21 
future incident cohorts.  By contrast, r*C and r*B  are the (per cycle) “intra-generation” 22 
discount rates.  We further assume that undiscounted incremental costs and benefits 23 
are the same for all incident cohorts. 24 
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From Equation 1, the ICERs for all future incident cohorts combined and for 1 
the first future incident cohort are equal if the cost and benefit discount rates, rC and 2 
rB, are equal.  Alternatively, if rC > rB, the ICER for all incident cohorts is lower (see 3 
Online Appendix).  For example, in the Netherlands, where costs are discounted at 4 
4% and benefits at 1.5% per year,12 under certain assumptions, the ICER for all 5 
future incident cohorts combined may be about ¾ of the ICER assuming a single 6 
incident cohort (i.e. as calculated in the traditional way) (see Online Appendix). 7 
 8 
When ntpt is equal for all t, Equation 1 simplifies to; 9 
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 13 
Now, if we assume that ntpt follows a -shaped quadratic curve, as is often the 14 
case with drug sales volumes,10 then Equation 2 is applicable again (see online 15 
Appendix).  If independent estimates of ntpt are available then they should be used in 16 
Equation 1, otherwise Equation 2 is appropriate.  Equation 2 is convenient since we 17 
need only have an estimate for the single parameter T, not the ntpt for all t. 18 
 19 
  20 
ICER for prevalent cohort 21 
In addition to the patients who will become eligible for the new technology in the 22 
future, there may be patients who are already eligible at the time the technology is 23 
introduced.  Such prevalent patients would switch from the current to the new 24 
technology.  Denoting the incremental costs and benefits of the prevalent cohort at 25 
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cycle j = 0….H , expressed per patient at the start of the prevalent cohort, by Cj, and 1 
Qj, the ICER for the prevalent cohort is; 2 
 3 
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 6 
ICER for incident and prevalent cohorts combined 7 
We define N as the number of patients in the prevalent cohort that are eligible for 8 
treatment, relative to the number of patients in the first future incident cohort, and p  9 
as the probability that a patient in the eligible prevalent cohort is given the new 10 
technology, assumed constant over cycle j.  Then in the general case of any number 11 
of treatments, the optimal strategy is to choose the treatment with the maximum 12 
expected net benefit13 (see Online Appendix).  Returning to the particular case of two 13 
treatments alternatives, we calculate the ICER as a “ratio of means”, in the 14 
terminology of Stinnett & Paltiel (1997).14  In particular, the ICER equals total 15 
incremental costs divided by total incremental benefits during the whole time the 16 
technology is used: 17 
 18 
ICER (prevalent and all future incident cohorts) =  19 
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In this equation we make the simplifying assumption that the proportion of patients in 1 
a given incident cohort that are given the new technology, pt, does not change over 2 
cycle j.  Note that if the cost and benefit discount rates are equal, then Equation 4 3 
implies that the ICER for the prevalent and incident cohorts combined will lie between 4 
the ICER for the prevalent cohort alone and the ICER for the first future incident 5 
cohort alone. 6 
We now introduce parameters to allow us to estimate N and p .  Denote the 7 
average age of patients at the start of any incident cohort as A (assumed constant 8 
over time).  Suppose a patient is eligible for treatment with the new technology over 9 
an average period of M years, from age A to age A+M.  To avoid confusion, note that 10 
parameter M relates to the age range of any given patient.  It should not be confused 11 
with parameter T, which relates to the age (lifetime) of the technology.  Costs directly 12 
associated with the technology occur during some, but not all the period of eligibility.  13 
For example, for patients in the incident cohort, the cost of a hip replacement occurs 14 
at the very start of the period of eligibility, whereas, the cost of a drug for a chronic 15 
condition might occur over the whole period of eligibility, M. 16 
When M is small, e.g. treatments for acute infection, the costs and benefits of 17 
the incident and prevalent cohorts are similar, because the patients’ initial 18 
parameters, such as the average age and average severity of condition are similar 19 
between the incident and prevalent cohorts (see below).  Conversely, when M is 20 
large, for example, for long-term therapies for chronic conditions, the costs and 21 
benefits of the incident and prevalent cohorts can be substantially different for a 22 
variety of reasons.  Hence the ICER for the prevalent cohort is similar to the ICER for 23 
the incident cohort for acute conditions, but can be very different for chronic 24 
conditions.  On average, we would expect that patients in the prevalent cohort will be 25 
approximately half way through their treatment with the comparator technology.  26 
Correspondingly, we expect that patients at the start of an incident cohort (i.e. at the 27 
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start of their treatment) to be treated for approximately twice the length of time as 1 
patients in the prevalent cohort. 2 
If the number of patients in the prevalent cohort that are eligible for treatment, 3 
relative to the number of patients in the first future incident cohort, N, is known from 4 
the literature, then this value should be used.  For example, the annual incidence of 5 
end-stage renal disease in the UK in 2003 was 5,517 patients, and the prevalence 6 
was 34,259,15 which gives N = 34,259 / 5,517 = 6.2.  Alternatively, we now describe 7 
how to estimate N.  Denote the probability that a patient who is treated with the 8 
comparator technology survives from age A, at the start of an incident cohort, to age 9 
A + t as ),( tAAs .  Such data are often available from cost-effectiveness models.  10 
Then; 11 
 12 
)1,(....)3,()2,()1,( 1321 MAAsnAAsnAAsnAAsnN M     13 
         (Equation 5) 14 
 15 
Hence when M is large, for conditions that require a long period of treatment, N is 16 
large, and when M is small, for conditions that require short-term treatment, for 17 
example acute infection, N is small.   18 
We estimate p  as the weighted average of the pt, with the weights equal to 19 
the number of patients in the prevalent cohort t years in the future; 20 
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where subscript -i refers to the incident cohort that started i years in the past.  Now 1 
suppose the cost and benefit discount rates are equal, i.e. vC = vB = v.  Then 2 
Equation 4 becomes; 3 
 4 
ICER (prevalent and all future incident cohorts) = 5 
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From which it is clear that the prevalent cohort is negligible when 
T
t
t
tt vpn
Np
0
 is 9 
small.  This is true when T is very large, or M is very small.  We now consider three 10 
cases; 11 
 12 
1: Parameters for both the incident and prevalent cohorts are known 13 
2: Parameters for incident cohort only are known 14 
3: Parameters for prevalent cohort only are known 15 
 16 
  17 
Case 1:  Parameters for incident and prevalent cohorts known 18 
Suppose we know the model parameters for both the incident and prevalent cohorts 19 
from literature reviews of primary research.  Then we can calculate Cj, Qj, Kj, and 20 
Bj.  We then calculate the ICER for the incident and prevalent cohorts combined 21 
from Equation 4, using an estimate of the pt and hence p  (as explained in the 22 
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Discussion).  To calculate the Cj, Qj, Kj, and Bj directly, we would need data 1 
from two types of clinical trial.  One trial (or trial subgroup) with patients from an 2 
incident cohort, i.e. newly diagnosed, and another trial with patients from the 3 
prevalent cohort.  This would be especially useful if patients respond differently to a 4 
new technology according to previous treatments received, for example, for 5 
corticosteroids for asthma.16 6 
If the prevalent cohort is large relative to the incident cohort, the range of 7 
values of input parameters, such as patient age and disease severity, for patients in 8 
the prevalent cohort may be wide.  In this case, it may be preferable to allow for such 9 
heterogeneity of input parameters in the cost-effectiveness model which is used to 10 
generate the Cj and Qj for the prevalent cohort.  For example, the model could be 11 
run for each of a range of patient ages, and the Cj and Qj estimated as a weighted 12 
average of the incremental costs and benefits for each model run, with weightings 13 
proportional to the probability density function of each age (e.g. as in Dewilde & 14 
Anderson 2004).17 15 
 16 
 17 
Case 2:  Parameters for incident cohort only known 18 
Suppose we know the parameter values for the incident cohort only, e.g. if the clinical 19 
trial(s) were based on incident cohorts of patients only.  We now outline a method for 20 
estimating the incremental costs and benefits for the prevalent cohort, Cj, Qj.  As 21 
above, we then calculate the ICER for the incident and prevalent cohorts combined 22 
from Equation 4.  In the Online Appendix, we describe an alternative method for 23 
estimating Cj and Qj, where we estimate the parameter values that specify the 24 
characteristics of patients at the start of the prevalent cohort.  Although this second 25 
method is simpler to implement than the first method, it is slightly less accurate 26 
because we assume no variability in the input parameters of the prevalent cohort. 27 
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Returning to the first method, suppose the costs in the incident cohort, 1 
expressed per patient at the start of the incident cohort, are Kj and K'j at cycle j = 2 
0…H for the new and comparator technologies respectively (Fig. 1).  As above, we 3 
assume that these costs are the same across all incident cohorts.  We cannot simply 4 
assume that the future costs with the new technology for the incident cohort that 5 
started in year t (i.e. in the past, so that t is negative), jtK , , j cycles since the start of 6 
the incident cohort, are given by Kj, because this would assume (incorrectly) that 7 
patients had been treated with the new technology in the past.  Instead, in the Online 8 
Appendix, we show how to estimate the jtK ,  by an algorithm, which can be coded as 9 
a macro.  The prevalent cohort costs and benefits for the new technology at cycle j = 10 
0…H are calculated as NnKC t
Mt
tjtj
1
)1(
, and NnQQ t
Mt
tjtj
1
)1(
,  and for the 11 
comparator technology as NnKC t
Mt
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and NnQQ t
Mt
tjj
1
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 (Fig. 1).   12 
 13 
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Case 3:  Parameters for prevalent cohort only known 15 
In the Online Appendix, we describe a method to estimate the incremental costs and 16 
benefits for the incident cohort, Kj, Bj, given that we know the parameter values, 17 
e.g. average age, for the prevalent cohort only.  As above, once we estimate Kj, Bj, 18 
we calculate the ICER for the incident and prevalent cohorts combined from Equation 19 
4.   20 
 21 
 22 
 23 
Example of application 24 
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Here, we apply the methods described above to an example cost-effectiveness 1 
model of a new maintenance drug versus an existing comparator drug to treat a 2 
chronic progressive condition.  Details of the model structure and results are given in 3 
the Online Appendix, however we provide a brief description here.  We assume that 4 
the new drug will be used in the health system for the next T = 30 years, and that the 5 
probability that a patient eligible for treatment takes the new drug at time t, pt, follows 6 
a -shaped quadratic curve.  The relative number of patients in the incident cohort, 7 
nt, is assumed equal over time t.  The new drug reduces the rate of disease 8 
progression.  Non-drug costs increase and utilities decrease with increasing disease 9 
severity.  The average age at diagnosis, i.e. at the start of an incident cohort, A = 30 10 
years, and we assume a certain distribution across disease severity states for 11 
patients in the incident cohort.  Patients were modelled from age 30 to death or age 12 
100.  This gives M = 70 years over which patients are eligible to be treated with the 13 
new drug.   14 
We estimate that the prevalent cohort is N = 47 times the size of a single 15 
incident cohort (Equation 5), and the average age of patients in the prevalent cohort 16 
is approx. 56 years, compared to A = 30 years in the incident cohort.  As expected, 17 
patients are at a more advanced stage of illness in the prevalent cohort compared to 18 
the incident cohort.  The ICER for the first incident cohort was calculated as £25,000 19 
per quality-adjusted life year (QALY).  Given that the cost and benefit discount rates 20 
were assumed equal, the ICER for all future incident cohorts combined was also 21 
£25,000 / QALY.  The total discounted costs and benefits for the prevalent cohort 22 
were calculated using the algorithm described in the Online Appendix (Fig. 2).  The 23 
ICER for the prevalent cohort alone was substantially higher, at £94,000 / QALY, and 24 
for both the prevalent and all incident cohorts combined, £57,000 / QALY. 25 
 26 
 27 
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 1 
Discussion 2 
In this paper we have argued that the cost-effectiveness of a treatment should be 3 
assessed in relation to all patients whose costs and benefits will be affected; both 4 
those currently eligible and those who will become eligible for the new treatment in 5 
the future.  On average, patients in the prevalent cohort will be older and will typically 6 
be at a more advanced stage of disease than patients in the incident cohort.  7 
Furthermore, the more life-years over which the technology is applicable for patients 8 
(e.g. maintenance therapies for chronic conditions), the greater these differences.  In 9 
summary, the suggestions in this paper are particularly important to implement in 10 
cost-effectiveness analysis in any of the following circumstances: 11 
 12 
 for long-term therapies for chronic conditions (particularly for chronic progressive 13 
conditions), e.g. Alzheimer’s disease, multiple sclerosis, cystic fibrosis, diabetes, 14 
eczema, rheumatoid arthritis. 15 
 when the discount rates for costs and benefits differ. 16 
 17 
In these cases, the ICER as calculated in this paper for all affected patients may 18 
differ substantially from the ICER as traditionally calculated (for the next incident 19 
cohort).  In particular, we have described a simplified but realistic example cost-20 
effectiveness analysis of a chronic progressive condition, assuming equal cost and 21 
benefit discount rates.  In this example, the ICER as calculated by our method is 2.3 22 
times the ICER as traditionally calculated by assuming just a single incident cohort, 23 
and 0.6 times the other traditional method of assuming a single prevalent cohort.   24 
We have shown that when the discount rates for costs and benefits differ, it is 25 
particularly important to estimate the costs and effectiveness of all future incident 26 
cohorts.  While many health economists,18 and most country’s official guidance for 27 
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the cost-benefit analysis of health technologies,12 recommend equal discount rates 1 
for costs and benefits the matter is by no means settled.  Some suggest rC should be 2 
greater than rB.
18-20  In particular, Brouwer et al (2005)19 recommend rC = 3.5% and rB 3 
= 1.5%, and Gravelle & Smith (2001)18 suggest that rC should be 2-5% greater than 4 
rB.  There remain some countries where different discount rates are recommended 5 
for health care economic evaluations (e.g. Netherlands: rC = 4%, rB = 1.5%; and 6 
Belgium: rC = 3%, rB = 1.5%; source, ISPOR website
12). 7 
An obvious question is: when the prevalent cohort is not negligible, when is 8 
the ICER for the prevalent cohort greater than the ICER for the first future incident 9 
cohort, and vice versa?  We suggest an answer to this question for three types of 10 
conditions-with-treatments.  First, we have shown that for the example cost-11 
effectiveness model of a continuous treatment for a progressive chronic disease, the 12 
prevalent cohort ICER is substantially greater than the incident cohort ICER, because 13 
at each cycle, the ratio of incremental costs to incremental benefits is greater for the 14 
prevalent cohort (Fig. 2 online Appendix).  This may be a typical result for a 15 
progressive chronic condition, supported by economic evaluations in cardiology.21  16 
Nevertheless, this question warrants further analysis, particularly since a contrary 17 
result has been found in a cost-effectiveness study of a cholesterol-lowering statin.22  18 
In this study, the incremental cost per life year gained was lower for older patients 19 
than for younger patients.  The difference in the ICERs was due to higher 20 
incremental costs in the younger age group, but similar incremental life years gained.  21 
Whilst these two patient groups did not correspond to incident and prevalent cohorts, 22 
this result does suggest that the prevalent cohort ICER may, in some cases, be lower 23 
than the incident ICER, given that patients in the prevalent cohort are, on average, 24 
older than those in the incident cohort.   25 
Second, we consider a continuous treatment for a non-progressive chronic 26 
condition, such as asthma.  Suppose there are two health states A and B, and 27 
patients are in the worse state A (e.g. poorly controlled asthma) under the 28 
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comparator drug and the better state B under the new drug.  Suppose further that life 1 
expectancy is independent of the drug and that costs are a function just of the drug 2 
(higher for the new drug) and whether the patient is in state A (higher) or state B 3 
(lower).  Further, suppose that patient utility is a function of just the state, and is 4 
higher in state B than in state A.  In this case, the ratios of incremental costs and 5 
benefits 
j
j
B
K
 and 
j
j
Q
C
 are constant over cycle j and are the same for the incident 6 
and prevalent cohorts.  Hence the prevalent cohort ICER equals the incident cohort 7 
ICER.   8 
Third, consider the scenario where the majority of costs are incurred up front 9 
for chronic conditions.  This is particularly appropriate for medical devices, such as 10 
cardiac pacemakers for heart conditions and cochlear implants for deafness.  Again, 11 
suppose there are two health states A and B, and suppose that patients are in the 12 
worse state A under the comparator technology and in the better state B under the 13 
new technology.  Again, suppose that life expectancy is independent of the 14 
technology.  Suppose the cost of the technology, e.g. cost of cochlear implant itself 15 
plus cost of implantation surgery, is incurred in the first cycle, and is greater for the 16 
new than the old technology.  Health state costs can be higher or lower in state A 17 
than in state B.  Patient utility is again solely a determined by health state.  In this 18 
case, for the incident and prevalent cohorts, the ratios of incremental costs and 19 
benefits 
j
j
B
K
 and 
j
j
Q
C
 are high in the first cycle, and far smaller in all future cycles.  20 
The ratios for the two cohorts are equal by cycle.  However, given that patients are 21 
older in the prevalent than in the incident cohort, and will therefore use the 22 
technology for fewer years, in the prevalent cohort, there will be fewer cycles with low 23 
incremental cost/benefit ratios.  Hence, the prevalent cohort ICER will be greater 24 
than the incident cohort ICER. 25 
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 18 
Another question is whether the ICER calculated according to our approach 1 
will be greater or smaller than the ICER as traditionally calculated.  In general, it is 2 
not possible to say: some technologies will appear more cost-effective, and others 3 
less cost-effective.  Consider first the case when the prevalent cohort is negligible 4 
compared to the incident cohort, for example with treatments for acute conditions.  5 
Then, if the cost and benefit discount rates are equal, the ICER will not change.  6 
Alternatively, if the discount rate for costs is greater than the rate for benefits, the 7 
ICER will be less than traditionally calculated.  Now, assume that the prevalent 8 
cohort is not negligible.  In previous model-based cost-effectiveness analyses, either; 9 
 10 
1: all patient-related parameters (e.g. average age, average disability level) refer 11 
to the prevalent cohort, or 12 
2: all patient-related parameters refer to the incident cohort, or 13 
3: some parameters refer to the prevalent cohort and the rest to the incident 14 
cohort. 15 
 16 
Again, assuming equal discount rates, in the expected scenario that the prevalent 17 
cohort ICER is greater than the incident cohort ICER, the combined ICER as 18 
calculated here would be lower than the ICER calculated in case 1, greater than in 19 
case 2, and uncertain in case 3.   Conversely, in the less likely event that the 20 
prevalent cohort ICER is lower than the incident cohort ICER, then these conclusions 21 
are reversed.  However, in a review of model-based cost-effectiveness analyses, we 22 
found very few studies that explicitly state whether model parameters were derived 23 
from incident or prevalent cohorts.  Therefore, our analysis suggests that the ICER 24 
as calculated in previous cost-effectiveness analyses may be substantially different 25 
from the ICER as calculated according to the methods of this paper.  As a side issue, 26 
note that we have assumed that the costs and benefits in all future incident cohorts 27 
are equal.  This assumption would be violated if, for example, one component of the 28 
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costs is predicted to increase in the future at a different rate to the other components 1 
of the costs.  Then we must adjust Equations 1, 2 and 4 appropriately. 2 
One disadvantage of our suggested methods is that they require estimation of 3 
additional model parameters.  The following algorithm may allow the analyst to 4 
decide when it is necessary to implement our suggested methods.  First, if the cost 5 
and benefit discount rates differ, our suggested method should be followed.  6 
Specifically, we must estimate the relative sizes of the affected patient populations 7 
(ntpt) for each year in the future up to year t = T (Equation 1).  If such data is not 8 
available, we suggest above that ntpt can be assumed a quadratic function of year t.  9 
We then require only an estimate of the lifetime of the new technology, T (Equation 10 
2).  Variability in ntpt and/or T should be incorporated in the probabilistic sensitivity 11 
analysis.  The values of ntpt, T, and the variability in these quantities could be 12 
estimated by analysing trends in the volumes of sales of similar technologies in the 13 
past. 14 
Next, what if the cost and benefit discount rates are equal?  When the size of 15 
the prevalent cohort is negligible compared to the size of the incident cohort, then the 16 
ICER for the prevalent cohort and all future incident cohorts combined can be 17 
approximated by the ICER for the first future incident cohort alone.  However, when 18 
the prevalent cohort is not small, the analyst should first compare the ICERs for the 19 
prevalent and incident cohorts.  Given that the ICER for both types of cohort 20 
combined lies between the ICER for the prevalent cohort and the ICER for the first 21 
future incident cohort when the cost and benefit discount rates are equal (see 22 
analysis), if the two ICERs are similar, then the ICER for the prevalent cohort and all 23 
future incident cohorts combined can be approximated by the ICER for either the 24 
prevalent cohort or the ICER for the first future incident cohort.  If the ICERs for the 25 
prevalent cohort and first future incident cohort are not similar, then our method for 26 
calculating a combined ICER should be used. 27 
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The proposed method requires estimates of nt and pt separately for each year 1 
in the future up to year t = T in order to estimate p  (Equation 6).  However, without 2 
relevant data, it is reasonable to assume that the nt are equal for all t.  The pt are 3 
then estimated as described in the estimation of ntpt above.  Next, we must estimate 4 
the size of the prevalent cohort relative to the size of the first future incident cohort, 5 
N, and patient-related parameters, such as the average age and average disability 6 
status for both the incident and prevalent cohort.   Uncertainty in N should also be 7 
reflected in the probabilistic sensitivity analysis.  Given that the ICER can be greatly 8 
altered by use of our proposed methods, the extra effort in estimating these 9 
parameters and in adjusting the cost-effectiveness analysis is justified.  Nonetheless, 10 
we are mindful of the extra analytical effort and data requirements that are implied by 11 
our methods.  We have therefore also provided some practical tools for estimating 12 
the costs and benefits for incident or prevalent patient cohorts when full data on the 13 
other type of cohort is unavailable.  Ideally, however, cost-effectiveness analyses in 14 
these situations should be grounded in rigorous empirical studies which yield 15 
separate effectiveness estimates and other data from both incident, newly eligible, 16 
patients and those prevalent patients who are switching to the new treatment. 17 
Given that the clinical and cost-effectiveness of a health technology can differ 18 
by patient subgroup, national guidance recommends assessing cost-effectiveness 19 
separately by patient subgroup (England,5 Australia,6 New Zealand,7 Canada,8 20 
Germany9).  The characteristics of patients in the subgroup should be identified on 21 
the basis of an a priori expectation of differential clinical or cost effectiveness due to 22 
known, biologically plausible mechanisms, social characteristics or other clearly 23 
justified factors.5  Disease severity is an example of such an a priori factor.  For 24 
example, consider a chronic progressive disease, with cost-effectiveness assessed 25 
for one mild disease subgroup and a severe disease subgroup.  As already 26 
explained, patients are on average more severely ill in the prevalent cohort than in 27 
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the incidence cohort.  Therefore we might expect the proportion of patients in the 1 
severe disease subgroup that are in the prevalent cohort to be higher than the 2 
proportion of patients in the mild disease subgroup that are in the prevalent cohort.  3 
In the extreme case, the severe subgroup might represent only patients in the 4 
prevalent cohort, and the mild subgroup only patients in the incident cohort.  In this 5 
case, the ICER for the severe subgroup would equal the prevalent cohort ICER 6 
(Equation 3), and the ICER for the mild subgroup would equal the ICER for all future 7 
incident cohorts combined (Equation 1).  In this special case, the technology might 8 
be deemed cost-effective for patients in the incident cohorts, but cost-ineffective for 9 
patients in the prevalent cohort, or visa versa.  Of course, cost-effectiveness is often 10 
assessed without splitting patients into subgroups according to disease severity.  For 11 
example, in the NICE appraisal of natalizumab for multiple sclerosis, patients in all 12 
Expanded Disability Status Scale levels from 0 (mild) to 10 (death) were combined to 13 
calculate a single estimate of cost-effectiveness (NICE 2007).23  In this case, the 14 
ICER should be estimated as in Equation 4. 15 
We have already outlined two possible areas for future research: the general 16 
conditions under which the prevalent cohort ICER is greater than the incident cohort 17 
ICER, and vice versa; and the estimation of the sizes of future incident cohorts, and 18 
the product life-time of a given technology, and their variability by analysis of trends 19 
in the volumes of sales of similar technologies in the past.  Now we suggest the 20 
following additional areas of research.  First, we have shown that cost-effectiveness 21 
is influenced by our methods when applied to an example simplified model.  Our 22 
methods could be applied to other existing cost-effectiveness models to explore their 23 
influence on cost-effectiveness.  Second, cost-effectiveness for our example model 24 
was rather dependent on the specific method used to estimate the costs and benefits 25 
for the prevalent cohort.  It would be interesting to investigate this for real cost-26 
effectiveness models.  Third, we have suggested how clinical effectiveness in our 27 
model may be parameterized from trial data.  We encourage investigation of the 28 
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availability of such clinical data for ‘real world’ models.  Fourth, in the previous 1 
paragraph, we describe how the proportion of patients in a patient subgroup that are 2 
in the prevalent cohort may depend on the subgroup.  We recommend investigating 3 
the extent to which patient subgroups differ in this respect in real decision problems.  4 
Finally, we have assumed that undiscounted incremental costs and benefits are the 5 
same for all incident cohorts.  Whilst we suggest that this is a reasonable assumption 6 
without evidence to the contrary, we encourage investigation into how factors such 7 
as the future prices of the health technology24, future changes in the median age at 8 
diagnosis, future changes in life expectancy and relative treatment effectiveness may 9 
influence this assumption. 10 
At present, most economic evaluations of health technologies simulate only 11 
the first incident cohort.  In this paper, we have argued that model-based economic 12 
evaluations should simulate the costs and benefits for all people who will be affected 13 
by a given health policy decision.  In particular, we have (a) demonstrated how to 14 
calculate the incremental cost-effectiveness of new health technologies when 15 
including the costs and benefits associated with either the current prevalent cohort or 16 
the future incident cohorts of patients, or both types of cohort together, and (b), using 17 
these equations, we have described the circumstances under which the ‘combined 18 
cohorts ICER’ is likely to differ from the ICER for the next incident cohort of patients. 19 
 20 
 21 
An Excel spreadsheet implementing the example cost-effectiveness model is 22 
available from the authors on request. 23 
24 
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Table 1.  Key parameters. 
 
 
Parameter 
 
 
Definition 
 
Kj, Bj 
 
incremental incident cohort cost and benefit between the new 
and comparator technology at cycle j = 0, 1, 2,…., H, expressed 
per patient at the start of the incident cohort 
Cj, Qj 
 
incremental prevalent cohort cost and benefit at cycle j = 0, 1, 
2,…., H, expressed per patient at the start of the prevalent 
cohort 
Kj, K'j incident cohort cost per patient for the new and comparator 
technology at cycle j = 0, 1, 2,…., H 
Cj , Qj prevalent cohort cost and benefit per patient for the new 
technology at cycle j = 0, 1, 2,…., H 
C'j , Q'j prevalent cohort cost and benefit per patient for the comparator 
technology at cycle j = 0, 1, 2,…., H 
Kt,j , Qt,j future costs and benefits per patient with the new technology for 
the incident cohort that started in year t (in the past, so that t is 
negative), j cycles since the start of the incident cohort 
 
H 
 
time horizon of each incident cohort in cycles 
 
rC , rB 
 
“inter-generation” annual cost and benefit discount rates 
 
vC , vB 
Cr1
1
, 
Br1
1
 
r*C , r*B “intra-generation” cost and benefit discount rates over a cycle 
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v*C , v*B 
Cr
*1
1
, 
Br
*1
1
 
T expected lifetime of new technology in years 
 
nt 
 
number of patients eligible for the new technology at the start of 
the incident cohort starting in year t = -H, … , -2, -1, 0, 1, 2,….,T, 
relative to the number of eligible patients at the start of the first 
year 
 
pt 
 
probability an eligible patient is given the new technology t = 
0….T years in the future 
 
p  
 
probability that a patient in the eligible prevalent cohort is given 
the new technology  
 
N 
 
number of patients in the prevalent cohort that are eligible for 
treatment, relative to the number of patients in the first future 
incident cohort 
 
A 
 
average age of patients at the start of the incident cohort 
 
s(A, A+t) 
 
probability a patient who is treated with the comparator 
technology survives from age A to A + t 
 
M 
 
number of years over which patients are eligible to be treated 
with the new technology 
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Figure 1. Prevalent and incident cohort costs for (a) the comparator and (b) the new 1 
technology.  Incident cohorts are shown as separate rows.  For simplicity, one cycle 2 
equals one year in this example.  Here, the technology is applicable on average to a 3 
given patient for M = 4 years (4 black cells in each row), and the prevalent cohort 4 
comprises M - 1 = 3 incident cohorts.  The future prevalent cohort comparator and 5 
new technology total costs at cycle j, NCj' and NCj equal the sum of the costs in the 6 
respective highlighted boxes. In (b), all costs before the assessment time (time zero) 7 
refer to the comparator technology, because the new technology was not used then.  8 
Costs directly associated with the technology occur in some, but not all the black 9 
cells.  For simplicity, we display costs only four years into the future, whereas the 10 
expected technology lifetime, T, will probably be much longer. 11 
 12 
Figure 2.  Undiscounted costs (£) over time in the example cost-effectiveness model.  13 
(a) displays the per patient comparator drug costs showing separately all incident 14 
cohorts that started in the past.  The costs in the future, i.e. to the right of the vertical 15 
line, comprise the costs of the prevalent cohort.  For clarity, a single example incident 16 
cohort is displayed in bold.  Costs initially rise as disease becomes more severe, thus 17 
incurring higher health state-related costs.  Costs eventually fall to zero as patients 18 
die.  (b) displays the same data for times in the past, but costs for the new drug in the 19 
future, i.e. for the new drug costs in the prevalent cohort.  (c) displays comparator 20 
drug costs.  In (c), the downward sloping line represents total costs in the prevalent 21 
cohort (summing over costs in all incident cohorts that started in the past), and the 22 
upward sloping line represents total costs in all future incident cohorts.  To 23 
demonstrate scale, the incident cohorts that make up these quantities, some of which 24 
are shown in (a), are just visible at the bottom of the graph.  We assume that there 25 
are the same number of patients in all incident cohorts. 26 
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Figure 1. 
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Figure 2. 
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